MedTrace Logo

CirculAting Tumor DNA in Patients DIagnosed With Lung Metastasis From Colorectal Cancer: candiDate Selection for Local AblaTive thErapy

NCT04704960 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2021-01-14

No results posted yet for this study

Summary

The investigators will detect circulating tumor DNA in blood of patients with lung metastases from colorectal cancer using NGS technology and intend to use it for predicting the outcome of local treatment (surgery or radiation) and recurrence of lung metastases.

Conditions

Interventions

OTHER

Diagnostic Test: liquid biopsy

detection of tumor DNA alteration in cf-DNA

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Seung-Tae Lee · Severance Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-28
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04704960 on ClinicalTrials.gov